Jichun Ma

Dr. Jichun Ma

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2021 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
TZTing-Juan Zhang
Ting-Juan Zhang
ZXZi-Jun Xu
Zi-Jun Xu
YGYu Gu
Yu Gu
JMJichun Ma
Jichun Ma
XWXiang-Mei Wen
Xiang-Mei Wen
JZJingdong Zhou
Jingdong Zhou
Background: Obesity confers enhanced risk for multiple diseases including cancer. The DNA methylation alterations in obesity-related genes have been implicated in several human solid tumors. However, the underlying role and clinical implication of DNA methylation of obesity-related genes in acute myeloid leukemia (AML) has yet to be elucidated.Results: In the discovery stage, we identified that DNA methylation-associatedLEPexpression was correlated with prognosis among obesity-related genes from the databases of The Cancer Genome Atlas. In the validation stage, we verified thatLEPhypermethylation was a frequent event in AML by both targeted bisulfite sequencing and real-time quantitative methylation-specific PCR. Moreover,LEPhypermethylation, correlated with reducedLEPexpression, was found to be associated with higher bone marrow blasts, lower platelets, and lower complete remission (CR) rate in AML. Importantly, survival analysis showed thatLEPhypermethylation was significantly associated with shorter overall survival (OS) in AML. Moreover, multivariate analysis disclosed thatLEPhypermethylation was an independent risk factor affecting CR and OS among non-M3 AML. By clinical and bioinformatics analysis,LEPmay be also regulated bymiR-517a/bexpression in AML.Conclusions: Our findings indicated that the obesity-related geneLEPmethylation is associated withLEPinactivation, and acts as an independent prognostic predictor in AML.

1 January 2016 in Clinical Laboratory
Verified
Journal Article
Closed access
TZTing-Juan Zhang
Ting-Juan Zhang
YWYu-Xin Wang
Yu-Xin Wang
DYDongqin Yang
Dongqin Yang
DYDong-Ming Yao
Dong-Ming Yao
LYLei Yang
Lei Yang
JQJun Qian
Jun Qian
MicroRNA-186 (miR-186) plays an important role in the pathogenesis of several cancers. Our study was intended to investigate the expression status and the prognostic implication of miR-186 in acute myeloid leukemia (AML). Real-time quantitative PCR was carried out in 112 de novo AML patients and 28 controls. The level of miR-186 expression in AML was significantly down-regulated compared to normal controls (p < 0.001). Patients with low miR-186 expression presented significantly older age than those with high miR-186 expression (p = 0.004). MiR-186high patients had a significantly higher frequency of CEBPA mutation than miR-186low patients (20% and 4%, respectively, p = 0.022). In addition, miR-186low patients had a significantly lower complete remission (CR) rate (30% vs. 53%, respectively, p = 0.028) than miR-186high patients. Moreover, miR-186low patients showed significantly shorter overall survival (OS) time than miR-186high patients in both whole AML and non-M3 patients (p = 0.023 and 0.026, respectively). Additionally, the adverse prognostic impact of miR-186 down-regulation was also shown in both whole AML and non-M3 patients without CEBPA mutation (p = 0.017 and 0.023, respectively). Our study suggests that miR-186 down-regulation is a frequent event and predicts poor prognosis in de novo AML patients.

10 July 2019 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
LTLi-Juan Tang
Li-Juan Tang
GSguokang sun
guokang sun
TZTing-Juan Zhang
Ting-Juan Zhang
JXJing Xu
Jing Xu
JZJingdong Zhou
Jingdong Zhou
JLJiang Lin
Jiang Lin
MicroRNA-29c (miR-29c) is abnormally expressed in several cancers and serves as an important predictor of tumor prognosis. Herein, we investigate the effects of abnormal miR-29c expression and analyze its clinical significance in acute myeloid leukemia (AML) patients. In addition, decitabine (DAC) has made great progress in the treatment of AML in recent years, but DAC resistance is still common phenomenon and the mechanism of resistance is still unclear. We further analyze the influences of miR-29c to leukemic cells treated with DAC. Real-time quantitative PCR (RQ-PCR) was carried out to detect miR-29c transcript level in 102 de novo AML patients and 25 normal controls. miR-29c/shRNA-29c were respectively transfected into K562 cells and HEL cells. Cell viability after transfection was detected by cell counting Kit-8 assays. Flow cytometry was used to detect apoptosis. MiR-29c was significantly down-regulated in AML (P < 0.001). Low miR-29c expression was frequently observed in patients with poor karyotype and high risk (P = 0.006 and 0.013, respectively). Patients with low miR-29c expression had a markedly shorter overall survival (OS) than those with high miR-29c expression (P < 0.001). Multivariate analysis confirmed the independent prognostic value of low miR-29c expression in both the whole cohort as well as the cytogenetically normal AML (CN-AML) subset. Over-expression of miR-29c in K562 treated with DAC inhibited growth, while silencing of miR-29c in HEL promoted growth and inhibited apoptosis. MiR-29c overexpression decreased the half maximal inhibitory concentration (IC50) of DAC in K562, while miR-29c silencing increased the IC50 of DAC in HEL. The demethylation of the miR-29c promoter was associated with its up-regulated expression. Although miR-29c demethylation was also observed in DAC-resistant K562 (K562/DAC), miR-29c expression was down-regulated. MiR-29c transfection also promoted apoptosis and decreased the IC50 of DAC in K562/DAC cells. Our results suggest that miR-29c down-regulation may act as an independent prognostic biomarker in AML patients, and miR-29c over-expression can increase the sensitivity of both non-resistant and resistant of leukemic cells to DAC.

1 September 2017 in Oncotarget
Verified
Journal Article
Open access
JZJingdong Zhou
Jingdong Zhou
JMJichun Ma
Jichun Ma
TZTing-Juan Zhang
Ting-Juan Zhang
XLXi-Xi Li
Xi-Xi Li
WZWei Zhang
Wei Zhang
JQJun Qian
Jun Qian
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Jing-Dong Zhou1, 3, *, Ji-Chun Ma2, 3, *, Ting-Juan Zhang1, 3, *, Xi-Xi Li1, 3, Wei Zhang1, 3, De-Hong Wu4, Xiang-Mei Wen2, 3, Zi-Jun Xu2, 3, Jiang Lin2, 3 and Jun Qian1, 3 1Department of Hematology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China 2Laboratory Center, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu, People’s Republic of China 3The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang, Jiangsu, People’s Republic of China 4Department of Hematology, The Third People’s Hospital of KunShan City, Suzhou, Jiangsu, People’s Republic of China *These authors have contributed equally to this work Correspondence to: Jun Qian, email: qianjun0007@hotmail.com Jiang Lin, email: linjiangmail@sina.com Keywords: ID2, expression, prognosis, TCGA, AML Received: June 22, 2017 Accepted: August 09, 2017 Published: September 01, 2017 ABSTRACT Dysregulation of ID proteins is a frequent event in various human cancers and has a direct role in cancer initiation, maintenance, progression and drug resistance. Our previous study has revealed ID1 expression and its prognostic value in acute myeloid leukemia (AML). Herein, we further reported ID2 expression and its clinical significance in AML. Real-time quantitative PCR was performed to detect ID2 transcript level in bone marrow mononuclear cells of 145 de novo AML patients. ID2 expression was significantly up-regulated in AML patients compared with controls. ID2 overexpression occurred with the highest frequency in poor karyotype (10/17, 59%), lower in intermediate karyotype (35/83, 42%), and the lowest in favorable karyotype (7/40, 18%). Moreover, high ID2 expression correlated with lower complete remission (CR) rate, shorter overall survival, and acted as an independent prognostic biomarker in whole-cohort AML and non-M3-AML patients. Importantly, the prognostic value of ID2 expression in AML was validated by The Cancer Genome Atlas (TCGA) data. In the follow-up of patients, ID2 expression at CR phase was decreased than at the time of diagnosis, and was increased again at the time of relapse. These findings demonstrated that bone marrow ID2 overexpression was a frequent event in AML patients, and predicts poor chemotherapy response and prognosis.

31 May 2016 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
DWDe-Hong Wu
De-Hong Wu
DYDong-Ming Yao
Dong-Ming Yao
LYLei Yang
Lei Yang
JMJichun Ma
Jichun Ma
XWXiang-Mei Wen
Xiang-Mei Wen
JQJun Qian
Jun Qian
Abnormal methylation of let-7a-3 has been found in various cancers and may consequently affect their survival. In this study, real-time quantitative methylation specific PCR (RQ-MSP) was used to determine the unmethylation level of let-7a-3 in 95 patients with myelodysplastic syndrome (MDS). The hypomethylation of let-7a-3 promoter was detected in 22 of 95 (23.2%) patients with MDS compared to 4.2% (1/24) of controls (p= 0.0419). Moreover, the frequency of let-7a-3 hypomethylation was higher in older patients (≥70 years) than in younger patients (<70 years). No significant difference was observed in distribution of WHO, IPSS, and cytogenetic classification. However, hypomethylated patients had significantly shorter overall survival than those without hypomethylation (p= 0.007). Moreover both Kaplan–Meier and Multivariate Cox analyses confirmed that let-7a-3 hypomethylation was an independent prognostic risk factor in cohorts of MDS patients with lower-risk disease. Our study suggested that let-7a-3 hypomethylation may predict poor outcome in MDS.

18 September 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
JMJichun Ma
Jichun Ma
XWXiangmei Wen
Xiangmei Wen
ZXZi-jun Xu
Zi-jun Xu
PXPeihui Xia
Peihui Xia
YJYe Jin
Ye Jin
JQJun Qian
Jun Qian
Acute myeloid leukemia (AML) is the most common type of hematological malignancy. Recently, an increasing number of reports have shown that many circular RNAs can act as effective targets for AML. However, the roles of circ_0059707 in AML remain largely unclear. In this study, we found that the expression levels of circ_0059707 were significantly decreased in AML patients with respect to normal controls (p < 0.001). Low expression levels of circ_0059707 were also associated with a poor prognosis. Furthermore, circ_0059707 overexpression inhibited cell growth and promoted apoptosis in leukemia cells, compared with control cells. Circ_0059707- and empty plasmid-transfected cells were injected subcutaneously into BALB/c nude mice. We found that the tumor volume was significantly lower in mice in the circ_0059707 group than in control mice (p < 0.01). Nuclear pyknosis, nuclear fragmentation, nuclear dissolution, and cell necrosis were observed in the circ_0059707 group by HE staining. CircInteractome analysis showed that 25 microRNAs (miRNAs), including miR-1287-5p, ©-miR-1825, a©hsa-miR-326, may be potential targets for circ_0059707. The expression of these miRNAs was analyzed in both the GEO GSE51908 and the GSE142700 databases. miR-1287-5p expression was lower in AML patients compared with controls in both the GSE51908 and the GSE142700 datasets. Moreover, we demonstrated that miR-1287-5p expression was down-regulated in AML patients and up-regulated in circ_0059707-overexpressing cells. Collectively, our research demonstrated that the down-regulation of circ_0059707 was highly evident in de novo AML patients. Our analysis also demonstrated that circ_0059707 inhibited cell growth and promoted apoptosis by up-regulating miR-1287-5p.